ArticleVirus genes2026
The use of an avian macrophage-like cell line (HD11) transduced with recombinant lentiviruses to dissect the immunomodulatory role of Marek's disease virus gene products.
Article in Virus genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Marek's disease (MD) is caused by the highly contagious Marek's disease virus (MDV), a tumorigenic alphaherpesvirus. The disease is presently managed through vaccination. Nevertheless, the dynamic nature of MDV presents challenges, as new virulent strains may arise that can potentially overcome existing vaccine-mediated immunity. To address this, new and more effective vaccines are crucial. The immune system's first line of defense against infections is the innate immune response, where type I interferons (IFN-I) play a key role. As with other alphaherpesviruses, MDV encodes numerous genes capable of modulating IFN-I production during infection. Ablation of these genes in MDV could result in attenuation, thereby facilitating the creation of novel vaccine strains with augmented IFN-I induction during infection. Hence, a system to identify immunomodulatory MDV gene products that impede IFN-I production in avian innate immune cells is required. Herein, we present an innovative screening method that quantifies the expression of Interferon Omega 1 (IFNω1) in an avian macrophage-like cell line expressing MDV genes via recombinant lentivirus (rLV) integration. Five MDV gene products hypothesized to inhibit IFN-I production (Meq, US3, R-LORF4, UL46, and UL48) were assayed in our screening system. Stable expression of all MDV genes was obtained when rLV was utilized to insert these genes into HD11 cells. Additionally, we established the optimal conditions for activation of the IFN-I response in HD11 cells using a 2 kb double-stranded DNA segment delivered by transfection as a stimulant. With this approach, we demonstrated that these MDV gene products significantly decreased the gene expression of IFN-I when activated by transfection with double-stranded DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.